Clinical trial · Interventional
Individualized Neoantigen Therapy with Unusual Radiotherapy Enhancement (iNATURE)
Individualized Tumor Neoantigen Peptide Vaccine in Combination with Unusual Immune Stimulating Radiotherapy in Refractory Solid Tumors (iNATURE) - a Phase II Randomized and Crossover Study
NCT06314087CI-TRIAL-00087617recruitingPhase 2ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
In this study, the investigators provide an individualized tumor neoantigen peptide vaccine in combination with radiotherapy to patients with advanced malignant solid tumors. The investigators observe the post-treatment tumor burden status, the immune response induced by immune preparations, and the prolongation of patient survival time, aiming to evaluate the effectiveness and safety of the individualized tumor neoantigen peptide vaccine in combination with radiotherapy
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Advanced Tumors | Neoplasm | CURATED_BROADER | 0.78 |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Placebo + conventional treatment including radiotherapy | Other | — | UNRESOLVED |
| Radiation: Radiation Therapy；Biological: Personalized tumor peptide vaccine | Combination Product | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- type
- ACTIVE_COMPARATOR
- label
- Control arm: Arm #1
- interventionNames
- Other: Placebo + conventional treatment including radiotherapy
- type
- EXPERIMENTAL
- label
- Experimental arm: Arm #2
- description
- Personalized tumor peptide vaccine + conventional treatment including radiotherapy group
- interventionNames
- Combination Product: Radiation: Radiation Therapy；Biological: Personalized tumor peptide vaccine
Primary outcomes (1)
- measure
- Progression free survival
- timeFrame
- Visits were conducted at the end (or termination) of each course and at 30, 90, and 120 days after the end of the last course for 4 months
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 80 Years
Show eligibility criteria text
Inclusion Criteria: 1. male or female 2. age\>18 years old 3. with advanced or recurrent malignancies diagnosed by pathology and imaging, who have failed systemic standard therapy or disease progression prior to enrollment and have no effective first-line therapy (for effective therapy, refer to the latest version of the treatment guidelines published by the Chinese Society of Clinical Oncology) 4. have at least one imaging measurable lesion 5. with an expected survival of ≥ 3 months 6. with an ECOG (Eastern Cooperative Oncology Group) score of 0-2 7. have access to sufficient tumor DNA (circulating tumor DNA or tissue samples) for analysis, or have genomic/exonic/transcriptional data from tumor and normal tissues and the data meet the analysis requirements, qualified for tumor neoantigen screening, or have prepared neoantigen peptides from a certified company (GMP) 8. women of childbearing age should have negative pregnancy tests within 7 days prior to enrollment, and have no short-term plans to have children and are willing to take protective measures (contraception or other birth control methods) before and during the clinical trial 9. compliant patients who is and able to follow the study protocol and the follow-up procedures Exclusion Criteria: 1. No neoantigens detected in the sequencing data. 2. with a history of bone marrow or stem cell transplantation 3. enrolled in other therapeutic clinical trials; clinical trials of Chinese medicine 4. with active bacterial or fungal infections 5. with active HIV (human immunodeficiency virus, human immunodeficiency virus), HCV (hepatitis C virus), HBV (hepatitis B virus), or the herpes virus (except for crusting for more than 4 weeks), or with respiratory viral infections (except for those who have been cured for more than 4 weeks) 6. with asthma, autoimmune disease, immunodeficiency 7. under treatment with immunosuppressive drugs 8. with severe coronary or cerebrovascular disease, or other conditions that concerns the investigator for enrollment 9. have clinical, psychological or social factors affecting informed consent or study implementation 10. have a history of drug or peptide allergy, or allergy to other potential immunotherapies 11. no decision making capacity for civil conduct
References
Publications (1)
- DERIVEDZhang Y, Hu YF, Ma L, Wu Y, Chao D, Chen X, Xu Z, Su X, Dai W, Huang J, Fu P, Kong FS. A phase II randomized trial of individualized neoantigen peptide vaccine combined with unusual radiotherapy (iNATURE) in advanced solid tumors-GCOG0028. Front Immunol. 2025 Aug 21;16:1538032. doi: 10.3389/fimmu.2025.1538032. eCollection 2025. PMID 40918097